Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Aspire BioPharma, Inc.

Company price
8.4 USD 0.10 ( 1.20%)
Last update at 2026-11-18T15:01:00Z
VOLUME
2323
Market Cap
0.99M

Momentum Score

…

Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
8.11
Low
8.70
High
52 Week Price Range
0.16
Low
35.01
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Available public filings identify Aspire BioPharma, Inc. (ASBP) as a small Nasdaq-listed specialty pharmaceutical company. Its long-term prospects appear to depend on progress of any development-stage assets, licensing or partnership deals, and access to capital that could support commercialization. Investors may find potential upside if clinical or strategic milestones are reached and disclosure improves.

Major risks include thin trading liquidity, dependence on external financing, unproven product candidates and regulatory and execution uncertainty.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
8.30
Dividend Yield
-
Revenue TTM
0.01M
Revenue Per Share
0.00
Gross Profit TTM
-0.00M
Debt / Equity
-0.22
ROE
-
Net Debt
0.38M
ROCE
308.11%
Diluted EPS TTM
-16.38

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -24.48M -12.54M 4.46M 3.34M -0.03M
Net income -24.48M -12.54M 4.46M 3.34M -0.03M
Selling general administrative 17.64M 3.09M 1.34M 0.98M 0.03M
Selling and marketing expenses 0.79M 0.13M 0.04M 0.05M -
Gross profit -0.00M 0.00M 0.00M 0.00M -
Reconciled depreciation - 0.00M 0.00M 0.00M -
Ebit - -1.21M 4.46M -0.60M -0.05M
Ebitda -19.35M -11.65M 5.80M 3.34M -0.03M
Depreciation and amortization - - 1.34M - 0.03M
Operating income -19.35M -3.09M -1.34M -0.98M -0.03M
Other operating expenses 19.36M 3.09M 1.34M 0.98M 0.03M
Interest expense 8.53M 0.89M 0.01M 0.00M -
Tax provision 0.00M 0.00M 0.00M 0.00M -
Interest income - 0.55M 5.81M - -
Net interest income -8.53M -0.34M 5.80M 0.00M -
Income tax expense - 0.00M 0.00M 0.00M -
Total revenue 0.01M 0.00M 0.00M 0.00M -
Total operating expenses 19.35M 3.09M 1.34M 0.98M 0.03M
Cost of revenue 0.01M 0.00M 0.00M 0.00M -
Total other income expense net -5.13M -9.45M 5.80M 4.32M 0.00M
Net income from continuing ops -24.48M -12.54M -0.36M -0.60M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1.31M 0.15M 19.98M 300.18M 0.29M
Other current assets 0.06M 0.11M 0.07M 0.60M 0.29M
Total liab 7.69M 1.69M 0.40M 11.12M 0.29M
Total stockholder equity -6.38M -1.54M 19.58M 289.07M -0.00M
Other current liab 5.19M 0.11M 0.24M 0.09M 0.05M
Common stock 0.00M 0.17M 19.90M 299.00M 0.00M
Capital stock 0.00M 0.02M 0.22M 0.22M -
Retained earnings -27.26M -2.78M -11.29M -9.94M -0.03M
Other assets - - - - -0.29M
Cash 1.00M 0.00M 0.01M 0.50M -
Total current liabilities 7.59M 1.69M 0.40M 0.30M 0.29M
Current deferred revenue - - - 0.00M -
Net debt 0.38M 1.26M 0.01M -0.50M 0.24M
Short term debt 1.38M 1.27M 0.01M 0.03M 0.24M
Short long term debt 5.18M 1.27M 0.36M 0.03M -
Short long term debt total 1.38M 1.27M 0.01M 0.03M 0.24M
Other stockholder equity 20.88M 1.22M 10.96M 0.76M 0.02M
Total current assets 1.31M 0.15M 0.08M 1.10M 0.29M
Net receivables - 0.04M - - -
Inventory 0.25M 0.00M - - -
Accounts payable 1.01M 0.31M 0.15M 0.18M 0.00M
Accumulated other comprehensive income - - 0.00M - -
Non currrent assets other - -6.67M -24.87M 298.79M 0.29M
Non current assets total 0.00M 6.67M 19.90M 299.08M 0.29M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.00M -0.08M -4.90M -
Total cashflows from investing activities - 13.78M 284.92M -294.69M -
Net borrowings 6.57M 0.00M - - -
Total cash from financing activities 5.92M 0.26M -284.76M 296.59M 0.00M
Net income -24.48M -1.31M 4.46M 3.34M -0.00M
Change in cash 1.00M -0.01M -0.50M 0.50M -
Begin period cash flow 0.00M 0.01M 0.50M 0.19M -
End period cash flow 1.00M 0.00M 0.01M 0.50M 0.19M
Total cash from operating activities -4.92M -0.27M -0.65M -1.41M -0.00M
Issuance of capital stock 0.27M 0.26M 0.00M 1.00M -
Depreciation 8.02M 0.00M 0.00M 0.00M -
Other cashflows from investing activities - -13.78M 284.92M -289.79M -
Change to inventory -0.25M 0.00M - - -
Change to account receivables - -0.04M - 0.40M -
Sale purchase of stock - -13.78M -284.92M - -
Other cashflows from financing activities -0.91M 11.98M - -0.30M 0.00M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital 0.53M 1.03M 0.69M -0.43M -0.00M
Stock based compensation 14.13M 0.00M - - -
Other non cash items -3.13M 0.01M -5.80M -4.32M 0.00M
Free cash flow -4.92M -0.27M -0.65M -1.41M -0.00M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
ASBP
Aspire BioPharma, Inc.
0.10
1.20%
8.40 - - 159.42 - 831.28
NVO
Novo Nordisk A/S
-0.64
1.57%
40.06 41.58 31.15 2.13 32.99 2.11
VRTX
Vertex Pharmaceuticals Inc
8.09
1.51%
542.29 30.22 24.27 10.36 6.50 9.99
REGN
Regeneron Pharmaceuticals Inc
2.85
0.30%
960.62 29.07 20.12 7.57 3.82 6.95
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38

Profile*

Aspire BioPharma, Inc.

Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.

23150 Fashion Drive, Estero, FL, United States, 33928

415 592 7399

Name Title Year Born
Mr. Kraig T. Higginson Interim CEO, President & Executive Chairman of the Board 1956
Mr. Ernest J. Scheidemann Jr. Chief Financial Officer 1961
Mr. Stephen E. Quesenberry General Counsel & Corporate Secretary 1964

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…